Recent studies have shown that CDK10 is a potential tumor suppressor in breast cancers, and CDK10/Ets2/c-RAF signaling has been demonstrated as an important determinant of breast cancer resistance to endocrine therapy [43]. This evidence concerns the gene ETS2 and neoplasm.